TransThera-B (02617): China Phase II Clinical Trial Approved for Tinengotinib Combined with Novel Hormone Therapy in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026 21:39
CST Updated
22:08
TransThera
Small Molecule Innovative Drug Research, Development, and Manufacturing